US Stock Insider Trading | Tyra Biosciences disclosed two insider trading transactions on February 13

K-LinePoet · 2026-02-13T22:08:44+00:00

Tyra Biosciences executive Bensen Daniel recently disclosed multiple insider trades, including selling 5,872 shares on February 12, 2026, at a price of $33.37. The company focuses on precision oncology and is dedicated to developing therapies to overcome tumor drug resistance.

K-LinePoet

2026-02-13 22:08:44

Abstract generation in progress

On February 13, 2026, Tyra Biosciences (TYRA) disclosed two insider trading transactions. Executive Bensen Daniel sold 5,872 shares on February 12, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 13, 2026	Executive	Bensen Daniel	February 12, 2026	Sell	2,128	31.50	$67,000
February 13, 2026	Executive	Bensen Daniel	February 12, 2026	Sell	5,872	33.37	$195,900
January 20, 2026	Executive	Bensen Daniel	January 12, 2026	Sell	1,017	29.08	$29,600
January 20, 2026	Executive	Bensen Daniel	January 12, 2026	Sell	6,983	28.44	$198,600
December 19, 2025	Director	MORE ROBERT J	December 19, 2025	Sell	10,000	25.00	$250,000
December 16, 2025	Executive	Bensen Daniel	December 12, 2025	Sell	8,000	22.64	$181,200
November 25, 2025	Director	MORE ROBERT J	November 21, 2025	Sell	246,900	20.25	$5,000,000
November 19, 2025	Executive	Bensen Daniel	November 18, 2025	Sell	75,600	16.07	$1,215,600
November 19, 2025	Executive	Bensen Daniel	November 19, 2025	Sell	50,000	16.32	$815,300
November 17, 2025	Executive	Bensen Daniel	November 13, 2025	Sell	1,111	16.00	$17,800

[Company Information]

Tyra Biosciences, Inc. was incorporated on August 2, 2018, in Delaware. The company is a precision oncology firm focused on developing targeted therapies to overcome tumor resistance and improve treatment outcomes for cancer patients. The company is utilizing its proprietary SNAP platform, which has been optimized to rapidly and accurately improve structural designs through iterative molecular snapshots, generating next-generation candidates specifically aimed at addressing acquired resistance and providing alternative treatment options.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.